Current treatment status-Undergoing active treatment-Progressive despite several lines of treatment - Page 18 of 24 Posts on Medivizor
Navigation Menu

Current treatment status-Undergoing active treatment-Progressive despite several lines of treatment Posts on Medivizor

A review of CAR-T cell therapy for CLL

A review of CAR-T cell therapy for CLL

Posted by on Jan 27, 2018 in Leukemia | 0 comments

In a nutshell This study reviewed CAR-T cell therapy, a new type of immunotherapy, for chronic lymphocytic leukemia (CLL). Some background Chimeric antigen receptor (CAR) T-cell therapy helps the immune system to fight cancer cells. In this treatment, immune cells (the T-cells) are removed from the blood. The T-cells are then genetically modified...

Read More

Current treatment options for patients with relapsed or difficult to treat mantle cell lymphoma

Current treatment options for patients with relapsed or difficult to treat mantle cell lymphoma

Posted by on Dec 4, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This review explores the current treatments for patients with relapsed or difficult to treat mantle cell lymphoma.  Some background Mantle cell lymphoma (MCL) is a type of non-Hodgkin lymphoma. Patients with relapsed MCL generally have poor outcomes. These patients with relapsed or difficult to treat (refractory) MCL have...

Read More

A review of venetoclax for previously treated CLL

A review of venetoclax for previously treated CLL

Posted by on Dec 2, 2017 in Leukemia | 0 comments

In a nutshell This study reviewed evidence on venetoclax (Venclexta) for previously treated chronic lymphocytic leukemia (CLL). Some background Targeted therapy is the standard treatment of CLL. This includes the BCL2 inhibitor therapy venetoclax. BCL2 inhibitor therapy blocks a protein called BCL2 involved in leukemia cell growth. Venetoclax has...

Read More

An analysis of abiraterone plus prednisone for metastatic castration-resistant prostate cancer

An analysis of abiraterone plus prednisone for metastatic castration-resistant prostate cancer

Posted by on Nov 8, 2017 in Prostate cancer | 0 comments

In a nutshell This study aimed to determine which patients  benefited most from abiraterone acetate (Zytiga) and prednisone (Deltasone). This study found that overall survival was increased for all patient groups that received this combination.  Some background A main treatment option for prostate cancer is androgen deprivation...

Read More

Lenalidomide treatment for patients with relapsed diffuse large B-cell lymphoma

Posted by on Oct 26, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at the safety and effectiveness of lenalidomide (Revlimid) to treat patients with relapsed diffuse large B-cell lymphoma. The authors concluded that lenalidomide is safe and effective for treating patients with relapsed diffuse large B-cell lymphoma, especially in patients with non-germinal center B-cell (GCB) like...

Read More

The use of a blood test to predict future outcomes for patients with relapsed diffuse large B-cell lymphoma

The use of a blood test to predict future outcomes for patients with relapsed diffuse large B-cell lymphoma

Posted by on Sep 26, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at how effective a blood test was at predicting future outcomes in patients with relapsed or difficult to treat diffuse large B-cell lymphoma. The study concluded that the lymphocyte-to-monocyte ratio blood test is very effective at predicting future outcomes for patients with relapsed or difficult to treat diffuse large...

Read More

Looking for patients with refractory multiple myeloma to test blinatumomab after autologous stem cell transplantation

Looking for patients with refractory multiple myeloma to test blinatumomab after autologous stem cell transplantation

Posted by on Sep 26, 2017 in Multiple Myeloma | 0 comments

In a nutshell This phase 1 clinical trial will test the safety of blinatumomab (Blincyto) treatment after high-dose melphalan (Alkeran) and autologous stem cell transplant in patients with refractory (unresponsive to treatment) multiple myeloma. The primary outcome will be measured by the number of adverse (negative) effects. The trial is being...

Read More

Looking for patients with relapsed or refractory multiple myeloma to test the safety and effectiveness of genetically engineered T-cells alone or with immunotherapy

Looking for patients with relapsed or refractory multiple myeloma to test the safety and effectiveness of genetically engineered T-cells alone or with immunotherapy

Posted by on Sep 26, 2017 in Multiple Myeloma | 0 comments

In a nutshell This early phase 1 clinical trial will test the safety and effectiveness of genetically engineered NY-ESO-1 specific (c259) T-cells cells with or without pembrolizumab (Keytruda) in treating relapsed or refractory (unresponsive to treatment) multiple myeloma. The details NY-ESO-1 is a protein found on many types of cancer cells...

Read More

Carfilzomib versus bortezomib in multiple myeloma that has not responded to treatment

Carfilzomib versus bortezomib in multiple myeloma that has not responded to treatment

Posted by on Sep 23, 2017 in Multiple Myeloma | 0 comments

In a nutshell This paper compared the use of carfilzomib (Kyprolis) and bortezomib (Velcade) in the treatment of multiple myeloma. This study concluded that carfilzomib was associated with a reduced risk of death compared with bortezomib. Some background Multiple myeloma is a cancer of the plasma cells. New treatments have led to longer survival...

Read More